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Dynamic spirometry and the lung transfer factor for CO (nC0) were determined in 41 non-smoking patients 
with sarcoidosis before and after steroid treatment. Dynamic spirometry revealed usual stage-dependent 
restrictive and/or obstructive abnormalities; only maximal expiratory flow rate at 75% FVC (MEF,,) was 
significantly increased after steroid treatment in stage 2 patients. The new finding is that TLC0 was increased 
in stage 1 [on average 21% above the predicted values (P.v.)], but it was decreased in stage 2 (11% below p.v.) 
and stage 3 (27% below p.v.). The increase in TLC0 in stage 1 was predominantly caused by an increase in 
7LCO membrane component (Dm) (33% above p.v.), while the pulmonary capillary blood volume (Vc’) 
increased less (19% above p.v.). Steroid treatment significantly reduced 7X0, Dm and Fc’ in stage 1 (for 14, 
17 and 18% of the respective baseline values), whereas it caused Z’LCO and Dm increases in stage 2 (for 8 and 
10% of the respective baseline values). In conclusion, a BCO in pulmonary sarcoidosis may not only be 
decreased in its advanced stages, but also exhibit increased values, which appeared related to the subclinical 
inflammatory reaction in the stage 1 patients. 
Introduction 
Pulmonary sarcoidosis is a disease of unknown 
origin characterized by the presence of non-caseating 
epitheloid cell granulomas preceded by an alveo- 
litis consisting of macrophages and activated 
T-lymphocytes (1,2). Physiological markers of the 
end-stage pulmonary sarcoidosis include reduced 
lung volumes, minimally impaired flow rates, 
decreased carbon monoxide transfer factor (nC0) 
and hypoxemia at rest (which is markedly exagger- 
ated during exercise) (3). Administration of cortico- 
steroids is known to be effective in relieving clinical 
symptoms and improving the radiographic course 
over short-term periods (4) however, long-term 
therapy has shown no therapeutic effects (5). 
We have already observed in some asbestos- 
exposed subjects a transient fiC0 increase, presum- 
ably due to increased permeability for CO of the 
alveolocapillary membrane, related to a subclinical 
inflammatory reaction (6,7). 
Since alveolitis is the common feature of early 
asbestosis and sarcoidosis, the aim of the present 
study was to investigate whether 7X0 or other 
functional tests differ among various stages of sarcoi- 
dosis and to examine the effect of predinosone. 
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Methods 
Forty-one non-smoking patients with biopsy- 
proven active pulmonary sarcoidosis were studied. 
There were 25 women and 16 men in all three stages 
of sarcoidosis (Table 1). They were derived from the 
consecutive group of 46 patients, by excluding smok- 
ers (n=2), those with history of chronic bronchitis 
(n=2) or clinically relevant left heart failure (n= 1). 
The diagnosis of sarcoidosis was established using 
the following criteria: (a) clinical and/or radiologic 
evidence of disease, (b) presence of non-caseating 
epitheloid granuloma on bronchial biopsies, and (c) 
absence of mycobacterial, fungal, or parasitic infec- 
tion and significant environmental exposure known 
to induce granulomatous lung disease. Chest roent- 
genograms were graded as follows: stage 0 was 
characterized with a normal chest roentgenogram, 
stage 1 by the presence of isolated hilar adenopathy, 
stage 2 by bilateral pulmonary micronodules with 
mediastinal adenopathy and stage 3 by bilateral 
micronodules without mediastinal adenopathy. 
Pulmonary function testing consisted of spiro- 
metry, flow-volume curves and the single breath 
7X0. Dynamic lung volumes [forced vital capacity 
(FVC); forced expired volume in 1 s (FEV,; FEV,/ 
FVC); maximal expiratory inflow at 75% of expira- 
tion (MEF,,)] were taken as the largest of at least 
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Table I Pulmonary function tests before and after steroid therapy in patients with pulmonary sarcoidosis” 
Chest roentgenogram 
Variables 
Stage 1 Stage 2 Stage 3 
(n=20) (n=l4) (n=7) 
Before After Before After Before After 
(1) (2) (3) (4) (5) (6) 
Sex (M/F) 
Age (yr) 
dFVC (RSD) 
dFEV, (RSD) 
dMEF,, (RSD) 
ATLCO (ROD) 
ATLCO/ VA (RSD) 
ADm (RSD) 
AVc’ (ROD) 
PaO, (mmHg) 
Hb (g dl - ‘) 
8/12 618 215 
;‘;; (‘s”, (ii) 
- 0.60 - 0.52 - 1.67t - 1.23 - 2.24tt - 2.09 
(0.06) (0.05) (0.17) (0.14) (0.45) (0.39) 
- 0.40 - 0.32 - 0.80 - 0.72 - 0.94 - 1.08 
(0.04) (0.04) (0.09) (0.08) (0.12) (0.15) 
- 0.57 - 0.38 - 1.16t - 0.73** - 1.25t - 1.16 
(0.06) (0.04) (0.13) (0.08) (0.18) (0.15) 
1.26 0.24** - 0.67j.t - 0.24* - 1.49tt - 1.33 
(0.24) (0.02) (0.08) (0.03) (0.24) (0.17) 
1.40 0.43** - 0.29tt - 0.12 - 1.84ttt - 1.68 
(0.15) (0.05) (0.03) (0.01) (0.50) (0.42) 
1.89 0.57*** 0.187 - 0.77s - 1.26tt - 1.43 
(0.22) (0.07) (0.02) (0.10) (0.27) (0.39) 
1.22 - 0.12** - 0.37t - O-25 - 2.04tt - 1.81 
(0.18) (0.02) (0.07) (0.05) (0.56) (0.39) 
(“9”, (“7: $4 :A 
77t 
(5) :7”, 
15.2 15.3 15.3 15.2 15.6 15.5 
(1.1) (1.2) (1.4) (1.3) (1.5) (1.6) 
“M=males, F=females, n=number of subjects, FVC=forced vital capacity, FEV, =forced expiratory volume in 1 s, 
MEF,,=maximum expiratory flow rate when 25% FVC remains, TLCO=diffusing lung capacity, V~=alveolar volume, 
Dm=membrane diffusing lung capacity, Vc’=pulmonary capillary blood volume, PaO,=arterial oxygen partial pressure, 
RSD=(observed value - predicted value)/standard deviation of the parameter. *P<O.O5 (3) rs. (4); **P<O.O05 (1) vs. (2) and 
(3) vs. (4); ***P<O.OOl (1) vs. (2) (Wilcoxon test). 
tP<O+lOl (1) vs. (3) or (5); ttP<0.0005 (1) vs. (3) or (5); tttP<O.OOOl (1) vs. (3) (Mann-Whitney test). 
three manoeuvres. The instrument used for these 
measurements was the computerized MASTERLAB 
from Jaeger, FRG. This instrument was calibrated 
daily: (a) volume calibration with 2-l handpump, (b) 
pressure calibration for box measurements, and (c) 
automatic checking of the proper gas mixture for 
nC0 measurements and zero calibration of carbon 
monoxide (CO) and helium (He) analysers. For 
single breath (10 s breathhold) YXO measure- 
ments, an inspired concentration of 0.3% CO, 
9% He, 21% O,, and balance N, was used. Each 
subject performed two tests and their average was 
considered a result. 
Membrane diffusing lung capacity (Dm) and 
pulmonary capillary blood volume (Vc’) estimations 
were made according to the Roughton and Forster’s 
formula (8): 
l/nCO= l/Dm+ l/Vc’O (1) 
where 0 is the rate of CO binding to haemoglobin 
and is generally dependent on the examinee’s mean 
oxygen tension in the pulmonary capillaries (Pc’O,), 
Hb and COHb, as follows (9): 
l/@(ml blood min mmHg ml - ’ CO) = [O.O06(Pc’O, 
(mmHg)+0~33]14~6/Hb(g dl- ‘) (1 - %COHb/lOO) 
(2) 
Pc’O, may be assessed as: 
Pc’O, = PAO, (mmHg) - 10 (3) 
or, more accurately, from oxygen consumption and 
Dm (9). In order to calculate Dm and Vc’ from 
equations 1-3, the measurements were made at two 
levels of alveolar oxygen tension: at room air and 
after breathing 100% oxygen for 10 min, providing 
the two equations with two unknowns: Dm and 
Vc’ (9). 
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Fig. 1 
Stage 1 Stage 2 Stage 3 
Mean TLC0 values, expressed in standardized 
residuals, before (pre) and after (post) prednisone therapy 
are shown in patients with various stages of pulmonary 
sarcoidosis. (~91) pre; ( n ) post. Prednisone therapy signifi- 
cantly decreased 7X0 in stage 1 (**P<O.O05), whereas 
there was a significant fiC0 rise in stage 2 (*P<O.O5). 
Patients with stage 2 or 3 had significantly lower TLC0 
(+P<O.O005) when compared with stage 1 patients. 
Results were expressed in standardized residuals, 
i.e. as (observed value - predicted value)/standard 
deviation of the particular parameter. The predicted 
values were derived from Cotes for spirometry (10) 
and Cotes and Hall for 7X0, ~~CO/VA, Dm and 
Vc’ (11). 
Before the Y’LCO test was performed each exam- 
inee was instructed in all required manoeuvres, 
emphasizing the importance of giving a sign when at 
the level of residual volume (maximal expiration), 
inhaling the test gas mixture rapidly to vital capacity, 
continuing to hold breath (assisted by the valve 
system) for 10 s, and exhaling a volume of at least 
2.0 1 rapidly. Two satisfactory tests were carried out 
with at least 4 min between the two tests. The sub- 
jects rested before testing for at least 30 min. One 
trained technician did 91% of the tests. All tests were 
performed between 0900 and 1300h. 
All patients were initially studied within 3 days 
from the common beginning of the study, and started 
therapy the day after the initial testing. All stage 2 
and stage 3 patients were treated with 30 mg day- ’ 
of prednisone for the first 2 months, afterwards the 
dose was lowered to 20 mg day - ’ for the last 2 
months. Stage 1 patients received 20 mg day ~ ’ for 2 
weeks. Each patient was restudied and the pulmo- 
nary function and arterial blood gases were measured 
the day after she (or he) completed the therapy. 
Arterial blood samples were analysed on an 
ABL-2 blood gas analyser (Radiometer, Denmark). 
This analyser was calibrated automatically each 
20 min. 
Values are expressed as mean & standard deviation 
(SD). Comparisons were made using non-parametric 
Mann-Whitney test (unpaired samples) or Wilcoxon 
test (paired samples). 2X0 precision was assessed 
by the method of Jensen et al. (13) which is designed 
for estimation of reproducibility of a parameter from 
a population in which only two repeated measure- 
ments can be made in a single individual. A P value 
less than 0.05 was considered significant. 
Forty-one patients with symptomatic pulmonary 
sarcoidosis were studied and were treated with pred- 
nisone. Pulmonary function tests (PFT) in various 
stages of sarcoidosis at the time of initial evaluation, 
as well as after prednisone therapy, are defined in 
Table 1. The following PFT were significantly 
decreased in stage 2 or 3 patients when compared to 
stage 1 patients: FVC (P<O.OOl, stage 2 vs. 1; 
P<O.O005, stage 3 vs. l), MEF,, (P<O.OOl, stages 2 
and 3 YS. l), 7X0 (P<O.O005, stages 2 and 3 vs. l), 
fico/vA (P<O.O005, stage 2 vs. 1; P<O.OOOl, stage 3 
vs. l), Dm (P<O.OOl, stage 2 vs. 1; P<O.O005, stage 3 
vs. l), Vc’ (P<O.OOl, stage 2 vs. 1; P<O.O005, 
stage 3 vs. l), Vc’ (P<O.OOl, stage 2 vs. 1; P<O.O005, 
stage 3 vs. 1) and PaO, (PcO.001, stage 3 vs. 1) 
(Table 1). 
Steroid treatment in stage 1 caused significant 
7UZ0, ~COII’A, Dm and Vc’ decrease, while these 
variables were 19-33% above the predicted values 
before the treatment (Table 1 and Fig. 1). Initially, 
pre-treatment 7tCO increase was related to increased 
Dm and vc’, Dm being the predominant contributor. 
However, in the stage 2 patients, prednisone 
increased MEF,,, TLC0 and Dm. Individual TLC0 
and Dm values before and after prednisone treatment 
in stage 1 are shown in Fig. 2. 
We underwent measurements of 7tCO in 32 
healthy controls on two consecutive days. Each sub- 
ject performed two tests and an average was taken, as 
in sarcoidosis patients. The means of RCO were 
104.1% and 106.4% of the values predicted according 
to Cotes and Hall (11). Thus, our normals appeared 
to exhibit slightly higher 7X0 values than in the 
report of Cotes and Hall, which was still the closest 
agreement, regarding the other published nC0 nor- 
mals (12). From these data, using the small sample 
method of Jensen et al. (13), the coefficient of vari- 
ation of 7rCO measurement in our laboratory can be 
assessed to be 4.7%. These tests were performed 
within 1 week from the beginning of the study. 
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Fig. 2 Individual TLC0 and Dm values, expressed in standardized residuals, before and after corticosteroid therapy in 20 
patients with stage 1 pulmonary sarcoidosis. 
The long-term stability of the measuring instru- 
ment is checked regularly in our laboratory each 
Friday, by measuring nC0 in one of the authors 
(J.T.) and one of the technicians. These checks 
revealed reproducible results over the period of this 
study (10 weeks). 
Discussion 
This study shows that in non-smoking patients 
with stage 1 pulmonary sarcoidosis, the lung transfer 
factor and particularly its membrane component may 
be increased. A part of the observed increase in 
7X0 can be attributed to the use of the predicted 
normal values of Cotes and Hall (II), since our 
control samples exhibited slightly higher values, on 
average for 5%. Since the mean RCO in our stage 1 
sarcoidosis patients was 121% of the predicted, it is 
highly probable that it still represents a supranormal 
finding. 
We hypothesized that this increased value of 7’1C0 
and Dm were related to an acute alveolitis. There- 
fore we administered an anti-inflammatory agent 
(prednisone) also to the stage 1 patients, where the 
clinically beneficial effect was not sought. Prednisone 
exhibited stage-dependent effect on 7tCO and its 
components: in stage 1 it decreased nC!O, 7X0/ 
VA, Dm and Vc’, whereas in stage 2 it increased 
7X0 and Dm. These findings support the original 
hypothesis of an acute inflammation present in some 
of the stage 1 sarcoidosis patients, stage 2 appeared 
as the partially reversible phase of a disease, whereas 
the stage 3 patients did not respond to prednisone. 
The majority of other investigators reported 
normal or slightly reduced values of RCO in early 
sarcoidosis [see for example (14,15)]. Still there are a 
few reports indicating that 5?,CO can be increased in 
stage 1 of sarcoidosis (16,17), and it even increased 
with the disease improvement in some subjects (16, 
their Table 5). 
Markers for monitoring the active inflammatory 
reaction in early pulmonary sarcoidosis other than 
7X0, exhibited results that are concordant with our 
hypothesis of a transient, inflammatory-mediated 
increased pulmonary permeability. In particular, in 
these patients the pulmonary gallium uptake was 
found to be increased and can be normalized utilizing 
steroid treatment (18). As widely investigated in 
human and animal studies (19-23) increased per- 
meability to inhaled hydrophilic molecules of 
99mTc-labelled diethylene-triamine-penta-acetate 
(99mTc-DTPA), which diffuses across the lung 
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epithelium paracellularly, peaks in acute inflamma- 
tion, remains elevated due to irreversible structural 
changes and becomes subnormal with increasing col- 
lagen deposition. The bronchoalveolar lavage (BAL) 
findings in sarcoidosis showed the increased 
CD4:CD8 T-lymphocyte ratio, which was normal- 
ized with corticosteroids (24). The increased serum 
angiotensin converting enzyme @ACE) concentra- 
tion in patients with sarcoidosis was reduced with 
corticosteroids (18). The transalveolar capillary 
gradient for albumin and glucose between plasma 
and alveolar epithelial lining fluid was modified in 
pulmonary sarcoidosis, suggesting that inflammation 
alters not only paracellular (20) but also transcellular 
transport processes (25). Since CO diffusion includes 
both paracellular and transcellular routes, a dynamic 
pattern is expected for 7X0, as well, on these 
theoretical grounds. 
We have reported previously in a longitudinal 
study that in early asbestosis, which is similar to 
sarcoidosis and characterized by abnormal 67Ga lung 
scans (26) and 99mTc-DTPA clearance (27) 7tCO 
was initially increased particularly in its membrane 
(Dm) component (6,7). Indomethacin treatment 
caused significant 7X0 and Dm reduction in com- 
parison with pre-treatment values (7). The local 
vasodilatation increased blood volume, and 
enhanced solubility of CO in the inflamed areas could 
cause increased 7KO. We found that 7KO was 
increased in the stage 1 sarcoidosis patients due to a 
predominant Dm increase, although a similar change 
was noted for Vc’. Increases in 7X0 have been 
described in other conditions in which similar mecha- 
nisms of inflammation and/or vascular engorgement 
could have intervened, e.g. pulmonary congestion (in 
atria1 septal defect, in early pulmonary oedema), an 
asthmatic attack, lung bleeding. 
Different effects of corticosteroids on the stage 1 
and stage 2 sarcoidosis patients may be explained by 
the anti-inflammatory action of corticosteroids: in 
stage 1 they prevent local vasodilatation and suppress 
CO solubility enhancement and thus lower 7’1C0, 
whereas in stage 2 they inhibit the increase in the 
thickness of the alveolo-capillary membrane, increas- 
ing RCO. Possible effect of 7’rCO reduction due to 
steroid-induced reduction in Hb (e.g. by a bleeding 
gastric ulcer) can be ruled out, since none of the 
examinees exhibited a material change in Hb after the 
therapy. 
Concluding, in sarcoidosis, the lung transfer factor 
may differ in various stages of a disease, being 
increased in some stage 1 patients, probably due to a 
subclinical inflammatory reaction. Consequently, 
anti-inflammatory corticosteroid therapy may reveal 
a different impact on 7X0, depending on the stage 
of pulmonary sarcoidosis. 
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